[February 04, 2016] |
|
Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015 - Research and Markets
Research and Markets (http://www.researchandmarkets.com/research/8d3p3f/chronic)
has announced the addition of the "Chronic
Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report
to their offering.
This report provides comprehensive information on the therapeutic
development for Chronic Lymphocytic Leukemia (CLL), complete with
comparative analysis at various stages, therapeutics assessment by drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic
development for Chronic Lymphocytic Leukemia (CLL) and special features
on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
-
Introduction
-
Chronic Lymphocytic Leukemia (CLL) Overview
-
Therapeutics Development
-
Pipline Products for Chronic Lymphocytic Leukemia (CLL) - Overview
-
Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative
Analysis
-
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by
Companies
-
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation
by Universities/Institutes
-
Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
-
Late Stage Products
-
Clinical Stage Products
-
Early Stage Products
-
Chronic Lymphocytic Leukemia (CLL) - Products under Development by
Companies
-
Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by
Universities/Institutes
-
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in
Therapeutics Development (Partial List)
-
4SC AG
-
AbbVie Inc.
-
Acetylon Pharmaceuticals, Inc.
-
Altor BioScience Corporation
-
Amgen Inc.
-
Aprogen, Inc.
-
Arno Therapeutics, Inc.
-
Astellas Pharma Inc.
-
Astex Pharmaceuticals, Inc.
-
AstraZeneca Plc
-
Bayer AG
-
BeiGene(Beijing) Co.,Ltd
-
Bellicum Pharmaceuticals, Inc.
-
Biogen, Inc.
-
BioInvent International AB
-
Bionovis SA
-
Biothera, Inc.
-
Boehringer Ingelheim GmbH
-
Bristol-Myers Squibb Company
-
Celgene Corporation
-
Cellectis S.A.
-
Cellular Biomedicine Group, Inc.
-
Coherus BioSciences, Inc.
-
CTI (News - Alert) BioPharma Corp.
-
Cyclacel Pharmaceuticals, Inc.
-
Eli Lilly and Company
-
Emergent BioSolutions Inc.
-
Epirus Biopharmaceuticals, Inc.
-
F. Hoffmann-La Roche Ltd.
-
Genentech, Inc.
-
Genor BioPharma Co., Ltd.
-
Gilead Sciences, Inc.
-
Grupo Ferrer Internacional, S.A.
-
Hospira, Inc.
-
Hutchison MediPharma Limited
For more information visit http://www.researchandmarkets.com/research/8d3p3f/chronic
View source version on businesswire.com: http://www.businesswire.com/news/home/20160204006078/en/
[ Back To TMCnet.com's Homepage ]
|